Table 9.
EGFR mutation, ALK and PD-L1 expression according to histologic subtype of NSCLC, patients’ gender and smoking status
| No. of patients (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PD-L1 expression | ||||||||||
| EGFR mutation-positive | EGFR mutation-negative | P value | ALK-positive | ALK-negative | P value |
TPS < 1% (None) |
TPS 1% to 49% (Low) |
TPS ≥ 50% (High) |
P value | |
| Adenocarcinoma (n = 147) | 70 (47.6%) | 77 (52.4%) | 8 (5.4%) | 139 (94.6%) | 57 (38.8%) | 61 (41.5%) | 29 (19.7%) | |||
| Male (n = 80) | 25 (31.3%) | 55 (68.8%) | < 0.0001 | 3 (3.8%) | 77 (96.3%) | 0.469 | 28 (35.0%) | 33 (41.3%) | 19 (23.8%) | 0.258** |
| Female (n-67) | 45 (67.2%) | 22 (32.8%) | 5 (7.5%) | 62 (92.5%) | 29 (43.3%) | 28 (41.8%) | 10 (14.9%) | |||
| Never smoker (n = 89) | 58 (65.2%) | 31 (38.4%) | < 0.0001 | 6 (6.7%) | 83 (93.3%) | 0.480 | 38 (42.7%) | 39 (43.8%) | 12 (13.5%) | 0.032** |
| Ever smoker (pack-years of smoking) (n = 58) | 12 (20.7%) | 46 (79.3%) | 2 (3.4%) | 56 (96.6%) | 19 (32.8%) | 22 (37.9%) | 17 (29.3%) | |||
| < 20 (Light smoker n = 10) | 3 (30.0%) | 7 (70.0%) | 0.725a | 1 (10.0%) | 9 (90.0%) | 0.167a | 6 (60.0%) | 4 (40.08%) | 0 | 0.004*** |
| 20–39 (Moderate smoker n = 14) | 3 (21.4%) | 11 (78.6%) | 1 (7.1%) | 13 (92.9%) | 4 (28.6%) | 8 (57.1%) | 2 (14.3%) | |||
| ≥ 40 (Heavy smoker n = 34) | 6 (17.6%) | 28 (82.4%) | 0 | 34 (100.0%) | 9 (26.5%) | 10 (29.4%) | 15 (44.1%) | |||
| Squamous cell carcinoma (n = 34) | 7 (20.6%) | 27 (79.4%) | 0 | 34 (100.0%) | 12 (35.3%) | 15 (44.1%) | 7 (20.6%) | |||
| Male (n = 28) | 4 (14.3%) | 24 (85.7%) | 0.086 | 0 | 28 (100.0%) | - | 10 (35.7%) | 11(39.3%) | 7 (25.0%) | 0.306** |
| Female (n = 6) | 3 (50.0%) | 3 (50.0%) | 0 | 6 (100.0%) | 2 (33.3%) | 4 (66.7%) | 0 | |||
| Never smoker (7) | 4 (57.1%) | 3 (42.9%) | 0.020 | 0 | 7 (100.0%) | - | 1 (14.3%) | 4 (57.1%) | 2 (28.6%) | 0.895** |
| Ever smoker (pack-years of smoking) (n = 27) | 3 (11.1%) | 24 (88.9%) | 0 | 27 (100.0%) | 11 (40.7%) | 11 (40.7%) | 5 (18.5%) | |||
| < 20 (Light smoker n = 5) | 2 (40.0%) | 3 (60.0%) | 0.535a | 0 | 0 | - | 2 (40.0%) | 2 (40.0%) | 1 (20.0%) | 0.326*** |
| 20–39 (Moderate smoker n = 5) | 0 | 5 (100.0%) | 0 | 0 | 1 (20.0%) | 2 (40.0%) | 2 (40.0%) | |||
| ≥ 40 (Heavy smoker n = 17) | 1 (5.9%) | 16 (94.1%) | 0 | 0 | 8 (47.1%) | 7 (41.2%) | 2 (11.8%) | |||
| Adenosquamous carcinoma (n = 9) | 4 (44.4%) | 5 (55.6%) | 0 | 9 (100.0%) | 2 (22.2%) | 5 (55.6%) | 2 (22.2%) | |||
| Male (n = 6) | 2 (33.3%) | 4 (66.7%) | 0.524 | 0 | 6 (100.0%) | - | 1 (16.7%) | 3 (50.0%) | 2 (33.3%) | 0.500** |
| Female (n = 3) | 2 (66.7%) | 1 (33.3%) | 0 | 3 (100.0%) | 1 (33.3%) | 2 (67.7%) | 0 | |||
| Never smoker (4) | 3 (75.0%) | 1 (25.0%) | 0.206 | 0 | 4 (100.0%) | 1 (25.0%) | 3 (75.0%) | 0 | 0.444** | |
| Ever smoker (pack-years of smoking) (n = 5) | 1 (20.0%) | 4 (80.0%) | 0 | 5 (100.0%) | 1 (16.7%) | 2 (33.3%) | 3 (50.0%) | |||
| < 20 (Light smoker n = 1) | 1 (100.0%) | 0 | 0 | 1 (100.0%) | 0 | 1 (50.0%) | 1 (50.0%) | 0.100*** | ||
| 20–39 (Moderate smoker n = 2) | 0 | 2 (100.0%) | 0 | 2 (100.0%) | 1 (50.0%) | 1 (50.0%) | 0 | |||
| ≥ 40 (Heavy smoker n = 2) | 0 | 3 (100.0%) | 0 | 2 (100.0%) | 0 | 0 | 2 (100.0%) | |||
TPS = Tumor proportion score
aComparison between EGFR mutation-positivity or ALK-positivity in heavy smokers versus light and moderate smokers
**Comparison between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS ≤ 50%) in male versus female and smokers versus never smokers
***Comparison between high PD-L1 expression (TPS ≥ 50%) versus no (TPS < 1%) and low PD-L1 expression (TPS ≤ 50%) in heavy smokers versus light and moderate smokers